Established in 2017, Astonea Labs Ltd. operates as a contract manufacturer of pharmaceutical and cosmetic products for clients across India and international markets. The company is involved in producing a wide range of formulations, including antibiotics, anti-cold medicines, antihistamines, as well as drugs addressing diabetes, cardiovascular diseases, gynaecological concerns, pain relief, fungal infections, and nutritional supplements. In the cosmetic space, Astonea Labs offers personal care items for skin, hair, and oral care in multiple forms such as gels, ointments, creams, lotions, oils, and serums. All products are developed and manufactured in adherence to established pharmaceutical and cosmetic industry norms. The company also deals in the trading of raw materials and packaging components used in these sectors.
Astonea Labs not only caters to contract manufacturing needs but also promotes its own brands in the domestic market—“Glow Up” and “Regero”—with plans to introduce a new brand, “Avicel.” Its presence extends beyond India through exports to countries like Iraq and Yemen. The company's dual strategy of serving as a manufacturing partner and building proprietary brands helps it tap into diverse market segments while ensuring quality compliance. The IPO aims to support its expansion, branding, and operational capabilities in the fast-evolving healthcare and personal care segments.